Modèle prédictif des effets du micro-environnement tumoral sur la concentration tumorale de VEGF pendant les traitements anti-VEGF
Volume 10, numéro 1, Mai 2015
[1]Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol. 2012;9:297-303.
[2]Hanahan D, Wienberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
[3]Arrell DK, Terzic A. Network systems biology for drug discovery. Clin Pharmacol Ther. 2010;8:120-5.
[4]Stefanini MO, Wu FTH, Mac Gabhann F. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res. 2010;70:9886-94.
[5]Finley SD, Popel AS. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J. 2012;14:500-9.
[6]Finley SD, Engel-Stefanini MO, Imoukhuede PI. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol. 2011;5:193.
[7]Chauhan VP, Stylianopoulos T, Martin JD. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7:383-8.
[8]Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A metaanalysis of VEGF distribution in cancer. Br J Cancer. 2007;97:978-85.
[9]Ljungberg B, Jacobsen J, Haggstrom-Rudolfssson S. Tumor vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res. 2003;31:335-40.
[10]Stimpfl M, Tong D, Fasching B. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res. 2002;8:2253-9.
[11]Yuan A, Yu CJ, Luh KT. Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR. Lab Invest. 2000;2000:11.
[12]Zygalaki E, Tsaroucha EG, Kaklamanis L. Quantitative realtime reverse transcription-PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non-small cell lung cancer. Clin Chem. 2007;53:1433-9.
[13]Houck K, Leung DW, Rowland AM. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;268:26031-7.
[14]Poon RTP, Lau CPY, Cheung ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 2003;63:3121-6.
[15]Poon RTP, Lau CPY, Ho JWY. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 2003;9:5339-45.
[16]Gutierrez J, Konecny GE, Hong K. A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF110 in ovarian cancer tumors. Clin Chem. 2008;54:597-601.
[17]Segerstrom L, Fuchs D, Backman U. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res. 2006;60:576-81.
[18]Willett CG, Boucher Y, Duda DG. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005;23:8136-9.
[19]Yang JC, Haworth L, Sherry RM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34.
[20]Lee J, Ku T, Yu H. Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT. Cancer Lett. 2012;318:221-5.
[21]Cao Y, E G, Wang E, Pal K. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 2012;72:3912-8.
[22]Adamcic U, Skowronski K, Peters C. The effect of bevacizumab on human malignant melanoma cells with function VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia. 2012;14:612-23.
[23]Lee TH, Seng S, Sekine M. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007;4:e186.
[24]Yuan A, Lin CY, Chou CH. Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS One. 2011;6:e16062.
[25]Rennel ES, Harper SJ, Bates DO. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol. 2009;5:703-12.
[26]Manetti M, Guiducci S, Romano E. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res. 2011;109:e14-e26.
[27]Nowak DG, Woolard J, Amin EM. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121:3487-95.
[28]Catena R, Larzabal L, Larrayoz M. VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Mol Cancer. 2010;9:320.
[29]Italiano JE, Richardson JL, Patel-Hett S. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet a-granules and differentially released. Blood. 2008;111:1227-33.
[30]Battinelli EM, Markens BA, Italiano Jr JE. Release of angiogenesis regulatory proteins from platelet alpha granules : modulation of physiologic and pathologic angiogenesis. Blood. 2011;118:1359-69.
[31]Verheul HMW, Lolkema MPJ, Quian DZ. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007;13:5341-7.
[32]Grunstein J, Masbad JJ, Hickey R. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol. 2000;20:7282-91.
[33]Tozer GM, Akerman S, Cross NA. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res. 2008;68:2301-11.
[34]Sanmartin E, Jantus E, Blasco A. Plasma levels of VEGF-A and VEGFR-2 in advanced NSCLC. J Clin Oncol. 2010;28 (15s):10623.
[35]Bernaards C, Hegde P, Chen D. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies. J Clin Oncol. 2010;28 (15s):10519.
[36]Jubb AM, Miller KD, Rugo HS. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011;17:372-81.
[37]Van Cutsem E, de Haas S, Kang Y-K. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119-27.